Nothing Special   »   [go: up one dir, main page]

HK49997A - Receptor protein for human B cell stimulating factor-2 - Google Patents

Receptor protein for human B cell stimulating factor-2

Info

Publication number
HK49997A
HK49997A HK49997A HK49997A HK49997A HK 49997 A HK49997 A HK 49997A HK 49997 A HK49997 A HK 49997A HK 49997 A HK49997 A HK 49997A HK 49997 A HK49997 A HK 49997A
Authority
HK
Hong Kong
Prior art keywords
receptor protein
human
stimulating factor
cell stimulating
mentioned
Prior art date
Application number
HK49997A
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Original Assignee
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27454721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK49997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tadamitsu Kishimoto filed Critical Tadamitsu Kishimoto
Publication of HK49997A publication Critical patent/HK49997A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK49997A 1988-01-22 1997-04-17 Receptor protein for human B cell stimulating factor-2 HK49997A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1238788 1988-01-22
JP1259988 1988-01-25
JP19488588 1988-08-04
JP746189 1989-01-14

Publications (1)

Publication Number Publication Date
HK49997A true HK49997A (en) 1997-04-25

Family

ID=27454721

Family Applications (1)

Application Number Title Priority Date Filing Date
HK49997A HK49997A (en) 1988-01-22 1997-04-17 Receptor protein for human B cell stimulating factor-2

Country Status (11)

Country Link
US (5) US5171840A (xx)
EP (1) EP0325474B1 (xx)
JP (1) JP2865300B2 (xx)
KR (1) KR0144861B1 (xx)
AT (1) ATE123295T1 (xx)
AU (1) AU615715B2 (xx)
CA (1) CA1341152C (xx)
DE (1) DE68922869T2 (xx)
ES (1) ES2072892T3 (xx)
HK (1) HK49997A (xx)
IL (1) IL89011A (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5518882A (en) * 1993-12-21 1996-05-21 Biotex Laboratories, Inc. Immunological methods of component selection and recovery
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
WO1996018416A1 (fr) * 1994-12-16 1996-06-20 Chugai Seiyaku Kabushiki Kaisha Inhibiteur d'expression contre le recepteur humain de l'interleukine-6
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
WO1998042377A1 (en) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
AU747883B2 (en) 1997-08-15 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
JP4124573B2 (ja) * 1998-03-17 2008-07-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
ES2353496T3 (es) 2002-02-14 2011-03-02 Chugai Seiyaku Kabushiki Kaisha Productos farmacéuticos en solución que contienen anticuerpos.
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
WO2007086490A1 (ja) 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
SI2041177T1 (sl) * 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
US8529895B2 (en) 2007-10-02 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
EP2217264B8 (en) * 2007-11-28 2013-02-27 Hadasit Medical Research Services and Development Ltd. Use of an il-6/il-6 receptor complex for preventing xerostomia induced by radiotherapy or chemotherapy
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
CN102388069B (zh) 2009-04-10 2016-01-20 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
NZ598127A (en) 2009-07-31 2014-03-28 Shin Maeda Cancer metastasis inhibitor
KR101985153B1 (ko) 2009-10-26 2019-05-31 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
KR20200133826A (ko) 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
MX2018002000A (es) 2015-08-18 2018-06-19 Regeneron Pharma Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
WO2020160465A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
EP4306127A1 (en) 2021-03-12 2024-01-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124697A (ja) * 1984-07-11 1986-02-03 Tanaka Kikai Sangyo Kk 船舶における圧力流体の冷却方法
AU8270187A (en) * 1986-10-28 1988-05-25 Memorial Sloan-Kettering Cancer Center Dna expressing fc receptor protein
JPS649774A (en) * 1987-07-02 1989-01-13 Fujitsu Ltd Thermal transfer printing method
JP2629712B2 (ja) * 1987-07-03 1997-07-16 日東紡績株式会社 インクジェット記録用紙
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2

Also Published As

Publication number Publication date
DE68922869T2 (de) 1995-10-19
US6410691B1 (en) 2002-06-25
US5990282A (en) 1999-11-23
KR0144861B1 (ko) 1998-07-01
EP0325474A3 (en) 1990-06-06
JP2865300B2 (ja) 1999-03-08
EP0325474A2 (en) 1989-07-26
AU615715B2 (en) 1991-10-10
ES2072892T3 (es) 1995-08-01
CA1341152C (en) 2000-12-12
IL89011A (en) 1995-03-15
JPH02288898A (ja) 1990-11-28
ATE123295T1 (de) 1995-06-15
US5480796A (en) 1996-01-02
US5851793A (en) 1998-12-22
IL89011A0 (en) 1989-08-15
DE68922869D1 (de) 1995-07-06
US5171840A (en) 1992-12-15
KR890012000A (ko) 1989-08-23
EP0325474B1 (en) 1995-05-31
AU2872089A (en) 1989-07-27

Similar Documents

Publication Publication Date Title
HK49997A (en) Receptor protein for human B cell stimulating factor-2
IL91705A0 (en) Interleukin-4 receptors,dna and expression vectors encoding them and process for producing the receptors
HUT43630A (en) Mammalian interleukine-4 and process for producing it
YU233582A (en) Process for the expression of a gene coded for human imunological interferon
IL68366A (en) Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture
PT85349A (en) Method for the preparation of proteins with factor viii activity by microbial host cells expression vectors host cells antibodies
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
IL58016A (en) Dna transfer vectors,microorganisms containing eucaryotic genes,proteins synthesized thereby and a method for synthesis of a eucaryotic protein by a microorganism
IE820069L (en) Recombinant dna encoding a polypeptide
IL89992A0 (en) Expression of human serum albumin in methylotrophic yeasts
GR3019059T3 (en) Human MK gene and protein sequence
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
AU2795989A (en) Production of gonorrheal pi proteins and vaccines
EP0776972A4 (en) GENE ENCODING THE IgG-Fc-BINDING PROTEIN
DE69431068D1 (de) Das polypeptid eines membran-proteins mit der funktion zur unterstützung des wachstums von prä-b zellen und sein gen
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
LTIP1543A (en) Process for enzymatic decomposition of recombinant proteins by means of iga-protease, fused protein, recombinant dna, cell
Kishimoto Antibodies against the receptor protein for human B cell stimulatory factor-2
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20090119